



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

tissue, placenta or other sources, also have notable functional differences. Furthermore, functionality of MSCs can change depending on culture conditions, number of passages, culture surface and stiffness, and various other factors. Different clonal populations of MSCs isolated from the same bone-marrow aspirate can vary substantially in functional attributes.⁴ These and related issues, including effects of MSC cryopreservation, continue to complicate the use of MSCs. Thus, despite a wealth of data showing that MSCs have beneficial actions in various preclinical acute lung injury models, much remains to be clarified. What exactly is an MSC and what is important about the potentially therapeutic actions and which population or preparation of MSCs might have best efficacy in any given clinical situation?⁵⁻⁷

It is becoming increasingly clear that the concept of immunopermissiveness inherent in the use of allogeneic MSCs is not accurate and that MSCs are stimulated by in-vivo factors after clinical administration to express HLA and other cell-surface molecules recognisable to the host immune system.⁶ A newly evolving concept suggests that MSCs rapidly undergo apoptosis, autophagy, or efferocytosis after systemic administration, and potentially also after intratracheal administration.^{6,8,9} As such, despite the ability of MSCs to release paracrine mediators, the host immune response to an apoptotic MSC might also greatly shape the actions that ameliorate inflammation or injury.^{8,9} In this context, the observation by Matthay and colleagues¹ that low MSC viability was correlated with poor efficacy should be investigated further. This finding supports the

argument that incorporating mechanistic and hypothesis-generating studies into any clinical investigation should continue.¹⁰ ARDS, however, remains a viable target for MSC-based cell therapies. We just need to figure out how to make them work.

Daniel J Weiss

University of Vermont, University of Vermont College of Medicine, Burlington, VT 05405, USA
dweiss@uvm.edu

I have received grants from National Institutes of Health, the Cystic Fibrosis Foundation, Medical technologies Enterprise Consortium, and United Therapeutics.

- 1 Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. *Lancet Respir Med* 2019; **7**: 154–62.
- 2 Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. *Lancet Respir Med* 2015; **3**: 24–32.
- 3 Dominici M, Nichols K, Srivastava A, et al. Positioning a scientific community on unproven cellular therapies: the 2015 International Society for Cellular Therapy Perspective. *Cytotherapy* 2015; **17**: 1663–66.
- 4 Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O'Connor KC. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. *Biotechnol Bioeng* 2011; **108**: 2716–26.
- 5 Sipp D, Robey PG, Turner L. Clear up this stem-cell mess. *Nature* 2018; **561**: 455–57.
- 6 Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell* 2018; **22**: 824–33.
- 7 Chinnadurai R, Copland IB, Garcia MA, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFN γ licensing. *Stem Cells* 2016; **34**: 2429–42.
- 8 Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. *Sci Transl Med* 2017; **9**: 1–11.
- 9 De Witte SFH, Luk F, Sierra Parraga JM, et al. Immunomodulation by therapeutic mesenchymal stromal cells is triggered through phagocytosis of MSC by monocytic cells. *Stem Cells* 2018; **36**: 602–15.
- 10 Simonson OE, Mouggiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. *Stem Cells Transl Med* 2016; **5**: 845.



ECMO in severe acute respiratory distress syndrome



Dr Barry Slavov/SPL

As summarised last year in a Comment in *The Lancet Respiratory Medicine*,¹ four randomised trials²⁻⁵ of extracorporeal membrane oxygenation (ECMO) have been done in patients with severe acute respiratory distress syndrome (ARDS) in the past 40 years. The 1979 and 1994 trials^{2,3} did not include a lung-protective ventilation strategy for patients in their control groups because they were done before publication of the US National Heart, Lung, and Blood Institute's ARDS Network-sponsored trial,⁶ which was published in 2000 and showed a major reduction in mortality with a low tidal volume and plateau pressure limited ventilation strategy. Since then, CESAR, the venovenous

ECMO trial⁴ that was published in 2009, showed that patients who were transferred to a centre that could institute ECMO had significantly lower mortality and severe disability at 6 months than those who were not transferred to an ECMO centre. However, the result was not definitive because only some of the patients referred to the ECMO centre received ECMO, and there was no evidence that patients in the control group received lung-protective ventilation. In the most recent trial, EOLIA,⁵ which was published in 2018, 60-day mortality was numerically lower in the venovenous ECMO group (35%) than in the control group (46%), in which patients received lung-protective ventilation, but

Published Online
January 11, 2019
[http://dx.doi.org/10.1016/S2213-2600\(18\)30507-1](http://dx.doi.org/10.1016/S2213-2600(18)30507-1)

See [Articles](#) page 163

this difference was not significant ($p=0.09$). For several secondary endpoints, however, ECMO was significantly better than the control group, including more days alive and free of the need for vasopressor therapy, renal replacement therapy, or prone positioning to treat their respiratory failure.⁵ The decision to stop the EOLIA trial for futility after enrolment of 249 patients, before the planned enrolment of 331 patients, was based on methods that can decrease power for rejection of the null hypothesis, and might have led to a type 2 error.⁷ The trial was powered for a 20% absolute reduction in mortality, which was probably an unrealistic goal.

In this context of uncertainty about interpretation of the results of the EOLIA trial⁵ and the increasing use of ECMO, Laveena Munshi and colleagues report the results of a systematic review and meta-analysis⁸ of the use of ECMO in adult patients with severe ARDS in this issue of *The Lancet Respiratory Medicine*. The authors included three observational studies and two randomised controlled trials, CESAR and EOLIA. For the three observational studies, matching methods were used to compare ECMO-treated patients with those who did not receive ECMO. Two of the observational trials were done primarily in patients with H1N1 influenza.

The primary analysis, which was restricted to the two randomised controlled trials (429 patients overall), showed that, compared with conventional mechanical ventilation, ECMO was associated with a reduced risk 60-day mortality (risk ratio [RR] 0.73 [95% CI 0.58–0.92]). ECMO was also associated with a reduced risk of treatment failure (0.58 [0.39–0.84]), which was defined as death in the ECMO group and death or crossover to ECMO in the control group. In a meta-analysis of all five studies, which included 773 patients overall, ECMO was associated with a reduced risk of 30-day mortality (RR 0.69 [95% CI 0.50–0.95]). However, this meta-analysis was prone to bias because of the inclusion of the observational studies, which did not include randomisation for ECMO treatment. Evidence also suggested that ECMO is associated with a risk of major haemorrhage. Munshi and colleagues concluded that the evidence favouring ECMO is of moderate-to-high quality according to the Grading of Recommendations Assessment, Development and Evaluation criteria. The availability of only two randomised controlled trials for this meta-analysis is an important limitation. It is unusual for a meta-analysis to be based on only two randomised

controlled trials, but the authors recognise this limitation and tried to adjust for heterogeneity between the trials. Despite this limitation, this meta-analysis is an important contribution because clinicians need guidance on how to interpret the evidence from CESAR⁴ and EOLIA.⁵ Although another trial of ECMO versus non-ECMO treatment for severe acute respiratory syndrome has been called for,¹ such a trial is not likely to be organised or funded, and if a trial were done it would not be completed for many years.

In addition to Munshi and colleagues' meta-analysis,⁸ Goligher and colleagues have done a Bayesian post-hoc analysis⁹ of the EOLIA trial. The Bayesian approach defines the probability of a treatment effect rather than ruling out the absence of a treatment effect as in conventional trial design. Goligher and colleagues used several estimates of posterior probabilities of enthusiasm or scepticism for efficacy of ECMO in patients with severe ARDS. The Bayesian analysis showed that, across a range of assumptions about the probability of benefit from early ECMO, the posterior probability of any mortality benefit with early ECMO in EOLIA was high, ranging from 88% to 99%. A 2018 clinical case analysis¹⁰ also provided a timely example of a patient with severe ARDS. The authors of that analysis addressed the question of whether or not to use ECMO in this clinical setting and provided both pro and con viewpoints.

In view of the results of the EOLIA trial,⁵ Munshi and colleagues' meta-analysis,⁸ and the Bayesian analysis of EOLIA,⁹ what should clinicians conclude about the use of ECMO in patients with severe ARDS? It is important for clinicians to be certain they have instituted other therapies before considering ECMO, including optimal lung-protective ventilation, diuresis, and neuromuscular blockade with deep sedation, prone positioning, and possibly inhaled nitric oxide, recruitment manoeuvres, and renal replacement therapy.¹¹ If these therapies do not stabilise the patient, and there are no other exclusion criteria (as in the EOLIA trial), I believe that the balance of evidence favours use of ECMO in severe ARDS if available from a medical centre experienced in provision of ECMO.

Michael A Matthay

Department of Medicine and Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco Moffitt Hospital, 505 Parnassus Avenue, San Francisco, CA 94143, USA
michael.matthay@ucsf.edu

MAM reports grants from Bayer, GlaxoSmithKline, the National Institute of Health, and the US Department of Defense, and personal fees from CSL Behring, Roche Genentech, Boehringer Ingelheim, and Cerus Therapeutics.

- 1 Derwall M, Roissant R. ECMO in severe acute respiratory distress syndrome. *Lancet Respir Med* 2018; **6**: 661–62.
- 2 Zapol WM, Snider MT, Hill JD, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. *JAMA* 1979; **242**: 2193–96.
- 3 Morris AJ, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal carbon dioxide removal for adult respiratory distress syndrome. *Am J Resp Crit Care Med* 1994; **149**: 295–305.
- 4 Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilation versus extracorporeal life support for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet* 2009; **374**: 1351–63.
- 5 Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 2018; **378**: 1065–75.
- 6 Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and acute respiratory distress syndrome. *N Engl J Med* 2000; **342**: 1301–08.
- 7 Sebillé V, Bellissant E. Comparison of the two-sided triangular test to the double triangular test. *Control Clin Trials* 2001; **22**: 503–14.
- 8 Munshi L, Walkey A, Goligher E, Pham T, Uleryk E, Fan E. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. *Lancet Respir Med* 2019; **7**: 163–72.
- 9 Goligher EC, Tomlinson G, Hajage D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. *JAMA* 2018; **320**: 2251–59.
- 10 My YM, Matthay MA, Morris AH. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 2018; **379**: 884–87.
- 11 Fielding-Singh V, Matthay MA, Calfee CS. Beyond low tidal volume ventilation: treatment adjuncts for severe respiratory failure in acute respiratory distress syndrome. *Crit Care Med* 2018; **46**: 1820–31.



ECMO for ARDS: from salvage to standard of care?

Published Online
January 11, 2019
[http://dx.doi.org/10.1016/S2213-2600\(18\)30506-X](http://dx.doi.org/10.1016/S2213-2600(18)30506-X)

This online publication has been corrected. The corrected version first appeared at thelancet.com/respiratory on January 29, 2019

The EOLIA randomised controlled trial,¹ which was published in 2018, did not show a significant difference in its prespecified primary endpoint of 60-day mortality between the extracorporeal membrane oxygenation (ECMO) group and the control group, who received conventional mechanical ventilation. However, the large and clinically important effect size noted in the trial,² a post-hoc Bayesian analysis³ of EOLIA data showing a high likelihood of survival benefit with ECMO even assuming a strongly sceptical prior distribution, and now a meta-analysis⁴ published in *The Lancet Respiratory Medicine* by Laveena Munshi and colleagues, all suggest that ECMO is efficacious in some adult patients with severe acute respiratory distress syndrome (ARDS).

Even with these results, some clinicians⁵ are calling for another confirmatory randomised controlled trial of ECMO in ARDS. Although theoretically appealing, another similar trial is unlikely. Such a study would require centres that are expert in the use of ECMO. In view of the strong trend toward a decrease in mortality in the ECMO group of EOLIA, many experienced ECMO practitioners would consider withholding of ECMO to be unethical in patients with very severe ARDS. Indeed, even before the results of EOLIA were known, clinical equipoise was problematic: 28% of patients in the control group were crossed over to ECMO. Furthermore, enrolment of 249 patients at 64 centres in EOLIA took 5.5 years. Another study similar to EOLIA is unlikely to be completed to definitively clarify whether ECMO reduces mortality in severe ARDS.

With this information in mind, where should ECMO fit into the treatment algorithm for ARDS? We believe that ECMO is indicated in patients with ARDS when other proven and less invasive strategies have been tried unsuccessfully.⁶ In most cases, ECMO—a highly invasive and resource-intensive technique—should not be used without first placing the patient in the prone position. Indeed this approach was used in the EOLIA trial.¹ Unfortunately, non-adherence to evidence-based management of ARDS is common, highlighting the need for the critical care community to improve adoption of proven therapies (mainly prone positioning; a high positive end-expiratory pressure strategy and neuromuscular blockade are also recommended but not as strongly).^{7,8} Centres that do not have evidence-based conventional management strategies should work with expert respiratory failure centres to optimise care, with transfer to the expert centres when warranted.

We propose a management algorithm (figure) culminating in early ECMO as used in the intervention group of the EOLIA trial¹—ie, when EOLIA criteria are met within 7 days of invasive mechanical ventilation, despite management with evidence-based conventional practices. Beyond this use, there are other scenarios when ECMO might be considered. The first we term rescue ECMO, which we define as cases when proven therapies in ARDS cannot be applied—eg, when the patient is too unstable for prone positioning and needs to rapidly undergo ECMO and the algorithm is thus bypassed out of perceived necessity. Separately, rescue ECMO also describes use of ECMO to